Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences

Molecular Oncology

Volumn 8, Issue 1, 2014, Pages 119-128

  Kimbung, Siker ^a   Kovács, Anikó ^b   Bendahl, Pär Ola ^a   Malmström, Per ^a,c   Fernö, Mårten ^a   Hatschek, Thomas ^d   Hedenfalk, Ingrid ^a  

^a LUND UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Claudin 2; Liver metastasis; Prognostic biomarker

Indexed keywords

CLAUDIN 2;

ADULT; ARTICLE; ASCITES; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER TISSUE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; MIDDLE AGED; PREMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SKIN METASTASIS; UPREGULATION;

BCSS; BREAST CANCER; BREAST CANCER SPECIFIC SURVIVAL; CI; CLAUDIN-2; CLAUDIN-2 MRNA; CLDN2; CONFIDENCE INTERVAL; ER; ESTROGEN RECEPTOR; HAZARD RATIO; HR; IHC; IMMUNOHISTOCHEMISTRY; LIMFS; LIVER METASTASIS; LIVER METASTASIS-FREE SURVIVAL; LNM; LYMPH NODE METASTASIS; ODDS RATIO; OR; PR; PROGESTERONE RECEPTOR; PROGNOSTIC BIOMARKER; RELAPSE-FREE SURVIVAL; RFS; TISSUE MICROARRAY; TMA;

BREAST; BREAST NEOPLASMS; CLAUDIN-2; COHORT STUDIES; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TRANSCRIPTOME; UP-REGULATION;

EID: 84892986572     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.10.002     Document Type: Article

References (42)

1. Bos M., Mendelsohn J., Kim Y.M., Albanell J., Fry D.W., Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res. 1997, 3:2099-2106.
2. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., Minn A.J., van de Vijver M.J., Gerald W.L., Foekens J.A., Massague J. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
3. Chebil G., Bendahl P.O., Idvall I., Ferno M. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer - clinical associations and reasons for discrepancies. Acta Oncol. 2003, 42:719-725.
4. Dhawan P., Ahmad R., Chaturvedi R., Smith J.J., Midha R., Mittal M.K., Krishnan M., Chen X., Eschrich S., Yeatman T.J., Harris R.C., Washington M.K., Wilson K.T., Beauchamp R.D., Singh A.B. Claudin-2 expression increases tumorigenicity of colon cancer cells: role of epidermal growth factor receptor activation. Oncogene 2011, 30:3234-3247.
5. Erin N., Wang N., Xin P., Bui V., Weisz J., Barkan G.A., Zhao W., Shearer D., Clawson G.A. Altered gene expression in breast cancer liver metastases. Int. J. Cancer 2009, 124:1503-1516.
6. Escaffit F., Boudreau F., Beaulieu J.F. Differential expression of claudin-2 along the human intestine: implication of GATA-4 in the maintenance of claudin-2 in differentiating cells. J. Cell Physiol. 2005, 203:15-26.
7. Furuse M., Furuse K., Sasaki H., Tsukita S. Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. J. Cell Biol. 2001, 153:263-272.
8. Goldhirsch A., Gelber R.D., Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J. Clin. Oncol. 1988, 6:89-97.
9. Harrell J.C., Prat A., Parker J.S., Fan C., He X., Carey L., Anders C., Ewend M., Perou C.M. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res. Treat. 2012, 132:523-535.
10. Hatschek T., Carlsson L., Einbeigi Z., Lidbrink E., Linderholm B., Lindh B., Loman N., Malmberg M., Rotstein S., Soderberg M., Sundquist M., Walz T.M., Hellstrom M., Svensson H., Astrom G., Brandberg Y., Carstensen J., Ferno M., Bergh J. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Res. Treat. 2012, 131:939-947.
11. Huang da W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
12. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
13. Imkampe A., Bendall S., Bates T. The significance of the site of recurrence to subsequent breast cancer survival. Eur. J. Surg. Oncol. 2007, 33:420-423.
14. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
15. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 2010, 28:3271-3277.
16. Kim T.H., Huh J.H., Lee S., Kang H., Kim G.I., An H.J. Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology 2008, 53:48-55.
17. Klintman M., Bendahl P.O., Grabau D., Lovgren K., Malmstrom P., Ferno M. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod. Pathol. 2010, 23:251-259.
18. Largillier R., Ferrero J.M., Doyen J., Barriere J., Namer M., Mari V., Courdi A., Hannoun-Levi J.M., Ettore F., Birtwisle-Peyrottes I., Balu-Maestro C., Marcy P.Y., Raoust I., Lallement M., Chamorey E. Prognostic factors in 1,038 women with metastatic breast cancer. Ann. Oncol. 2008, 19:2012-2019.
19. Malmstrom P., Bendahl P.O., Boiesen P., Brunner N., Idvall I., Ferno M. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer. J. Clin. Oncol. 2001, 19:2010-2019.
20. Mano M.S., Cassidy J., Canney P. Liver metastases from breast cancer: management of patients with significant liver dysfunction. Cancer Treat. Rev. 2005, 31:35-48.
21. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
22. Norton L., Massague J. Is cancer a disease of self-seedingα. Nat. Med. 2006, 12:875-878.
23. Pentheroudakis G., Fountzilas G., Bafaloukos D., Koutsoukou V., Pectasides D., Skarlos D., Samantas E., Kalofonos H.P., Gogas H., Pavlidis N. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res. Treat. 2006, 97:237-244.
24. Peter Y., Comellas A., Levantini E., Ingenito E.P., Shapiro S.D. Epidermal growth factor receptor and claudin-2 participate in A549 permeability and remodeling: implications for non-small cell lung cancer tumor colonization. Mol. Carcinog. 2009, 48:488-497.
25. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., He X., Perou C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
26. Reyes J.L., Lamas M., Martin D., del Carmen Namorado M., Islas S., Luna J., Tauc M., Gonzalez-Mariscal L. The renal segmental distribution of claudins changes with development. Kidney Int. 2002, 62:476-487.
27. Ridyard A.E., Brown J.K., Rhind S.M., Else R.W., Simpson J.W., Miller H.R. Apical junction complex protein expression in the canine colon: differential expression of claudin-2 in the colonic mucosa in dogs with idiopathic colitis. J. Histochem. Cytochem. 2007, 55:1049-1058.
28. Singh A.B., Sugimoto K., Dhawan P., Harris R.C. Juxtacrine activation of EGFR regulates claudin expression and increases transepithelial resistance. Am. J. Physiol. Cell Physiol. 2007, 293:C1660-C1668.
29. Singletary S.E., Walsh G., Vauthey J.N., Curley S., Sawaya R., Weber K.L., Meric F., Hortobagyi G.N. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003, 8:241-251.
30. Smid M., Wang Y., Zhang Y., Sieuwerts A.M., Yu J., Klijn J.G., Foekens J.A., Martens J.W. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68:3108-3114.
31. Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. Hum. Pathol. 2004, 35:1531-1536.
32. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 2005, 46:551-560.
33. Solomayer E.F., Diel I.J., Meyberg G.C., Gollan C., Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res. Treat. 2000, 59:271-278.
34. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 2009, 360:790-800.
35. Szasz A.M., Tokes A.M., Micsinai M., Krenacs T., Jakab C., Lukacs L., Nemeth Z., Baranyai Z., Dede K., Madaras L., Kulka J. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin. Exp. Metastasis 2010, 28:55-63.
36. Tabaries S., Dong Z., Annis M.G., Omeroglu A., Pepin F., Ouellet V., Russo C., Hassanain M., Metrakos P., Diaz Z., Basik M., Bertos N., Park M., Guettier C., Adam R., Hallett M., Siegel P.M. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2011, 30:1318-1328.
37. Tabaries S., Dupuy F., Dong Z., Monast A., Annis M.G., Spicer J., Ferri L.E., Omeroglu A., Basik M., Amir E., Clemons M., Siegel P.M. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol. Cell Biol. 2012, 32:2979-2991.
38. Thakur A., Rahman K.W., Wu J., Bollig A., Biliran H., Lin X., Nassar H., Grignon D.J., Sarkar F.H., Liao J.D. Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol. Cancer Res. 2007, 5:171-181.
39. The R Project for Statistical Computing. http://www.r-project.org.
40. Weber C.R., Nalle S.C., Tretiakova M., Rubin D.T., Turner J.R. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008, 88:1110-1120.
41. Weigelt B., Glas A.M., Wessels L.F., Witteveen A.T., Peterse J.L., van't Veer L.J. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl. Acad. Sci. U S A 2003, 100:15901-15905.
42. Yardley D.A. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin. Breast Cancer 2010, 10:64-73.